Ligand Pharmaceuticals Incorporated (LGND) Stock: Price, Forecast & Analyst Target
Ligand Pharmaceuticals Incorporated (LGND) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $286.85 (-0.03%), as of the Nov 20, 2026 trading session; market cap $5.74B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Ligand Pharmaceuticals Incorporated · LGND · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Ligand supplies both commercialized drugs across cancer, infectious disease, and bone health, and collects royalties from partner programs—a mix of direct sales and passive income flows. Whether the royalty foundation will cushion earnings through product cycles or whether the company must continually expand its own portfolio determines whether this business compounds or merely treads water.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Ligand Pharmaceuticals (LGND)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, but a fragile balance sheet and an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
Enterprise value relative to EBITDA is the main valuation drag relative to sector peers.
- quarterly revenue $115M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 3.36 · Piotroski F 5
Holding back: balance-sheet strain, a rich price
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 74 | Strong | |
| 74 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 71 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $286.85 | |
| Change on the day | -0.03% | |
| 52-week range | $175.89–$326.63 | |
| Market capitalisation | $5.74B | — |
| Price / earnings (trailing) | 113.44 | |
| Shares traded on the day | 259.8K | |
| Beta (volatility vs the S&P 500) | 1.03 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Ligand Pharmaceuticals (LGND): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Ligand Pharmaceuticals (LGND), and what does it report?
Short answer · as of
Ligand maintains two revenue streams: direct sales from its own marketed drugs and royalties on partner-developed therapeutics.
Research dated 2026-09-13.
This dual model produces exceptionally high gross margins because royalties require minimal fulfillment cost.
The financial statements separate royalty income from product sales, contract revenue, and Captisol material sales. Operating leverage emerges from the fact that royalty income grows with partner drug adoption while requiring little incremental spending.
What do the latest results show for Ligand Pharmaceuticals (LGND)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $115M.
Research dated 2026-09-13.
The most recent quarter showed strong profitability and higher revenue than the prior quarter, with earnings per share materially positive. This reversal followed a period of losses and suggests demand has strengthened.
Management projects the just-closed acquisition will contribute meaningfully to earnings in coming periods, with the acceleration weighted toward later periods. The magnitude of the contribution is substantial enough to move company-wide earnings power.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $78.75M Oct 29, 2026
- Latest report · revenue estimate
- $77.00M Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $78.75M | $77.00M | $2.6700 | $2.3300 |
| Aug 6, 2026 | $63.69M | $61.30M | $2.3700 | $2.0100 |
| May 14, 2026 | $51.72M | $59.10M | $1.6300 | $1.8400 |
| Feb 26, 2026 | $59.67M | $55.59M | $2.0200 | $1.4600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $115M | $117M | $5.68 (diluted) |
| Q4 FY2025 | $60M | $45M | $2.12 (diluted) |
| Q1 FY2026 | $52M | -$13M | -$0.67 (diluted) |
| Q2 FY2026 | $64M | $49M | $2.22 (diluted) |
What are the financial strengths and risks for Ligand Pharmaceuticals (LGND)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The company holds cash substantially exceeding its debt, with liquidity ratios that indicate minimal near-term financing pressure. Quarterly operating results have been strong lately, translating to robust cash generation.
The risk lies in revenue concentration—a slowdown in major royalty-generating drugs would hollow out earnings—and in execution risk of bringing new programs to market if royalty partners falter. The company's small headcount also means that key personnel departures could disrupt operations.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 113.44 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Ligand Pharmaceuticals (LGND)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13.
Watch whether the recent acquisition delivers the projected earnings accretion and whether management's confidence in back-half contribution timing holds up. Equally important: track adoption trends for the major royalty-generating drug franchise.
Monitor whether the company returns to repurchasing shares, a signal that management believes the valuation is attractive relative to intrinsic value. Any material new clinical readouts from development programs warrant close attention.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The newest quarter held here (Q3 FY2025) was filed Nov 7, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Ligand Pharmaceuticals compare with its peers?
Short answer
Ligand Pharmaceuticals's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Ligand differs from traditional pharmaceutical companies by deriving substantial income from royalty arrangements, which provides earnings stability during slow periods for its own portfolio. Unlike pure-royalty vehicles, it maintains its own marketed drugs with direct pricing power.
The lean headcount for a company of its revenue scale suggests a highly efficient model with outsourced development and commercial execution, which reduces fixed costs but increases dependence on partner execution and regulatory approval timelines.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $63.34 Nov 20, 2026 | $9.57B | 90 5-pillar Nov 18, 2026 | |
| $121.40 Nov 20, 2026 | $7.92B | 88 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $46.53 Nov 20, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| Ligand Pharmaceuticals (LGND) — this page | $286.85 | $5.74B | 71 |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| $127.38 Nov 20, 2026 | $5.17B | 64 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $326.00 – $406.00
- Consensus target
- $350.00
- Median target
- $345.00
Consensus record · Captured .
Measured against a quoted price of $286.85 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 125
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 74
- Other transactions
- 51
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LGND in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LGND in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ligand Pharmaceuticals (LGND)?
- Ligand Pharmaceuticals (LGND) Stock May Be A Bargain On Royalty Cash Flows
- Ligand Pharmaceuticals Insider Sold Shares Worth $960,141, According to a Recent SEC Filing
- Barclays Raises Price Target for Ligand Pharmaceuticals
- Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350
Ligand Pharmaceuticals Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Captisol and why does Ligand sell it?
Captisol is a proprietary solubilization technology that Ligand developed and now supplies to pharmaceutical manufacturers. Many of Ligand's own drugs use Captisol, but competitors also license and purchase it, creating a recurring material revenue stream. This segment diversifies revenue away from pure drug sales and provides high-margin, relatively non-volatile income.
Does Kyprolis generate most of Ligand's royalty income?
Kyprolis is a major contributor to royalty income, as a marketed cancer drug with established market share. However, the company also collects royalties from other partner drugs across its portfolio, spreading concentration risk. A sustained decline in Kyprolis adoption would meaningfully compress earnings, but would not eliminate the royalty base entirely.
Why did earnings swing so dramatically between quarters?
Pharmaceutical and royalty revenue can be lumpy, driven by partner sales, milestone achievements, and one-time adjustments. The swing from a material loss in the prior quarter to strong profitability reflects both cyclical partner performance and possibly upfront payments or milestone revenues. The company's business model amplifies these swings because operating leverage is high—a small change in royalty collections or partner sales drives large percentage changes in net income.
Is the cash balance enough to fund the development pipeline without raising capital?
The company holds substantial liquid assets relative to its burn rate and development commitments. At the current operating cash flow trajectory, the runway appears to extend many years without dilutive financing. However, if major partner programs fail or new acquisitions accelerate, capital needs could rise sharply. The company has historically been willing to acquire programs and clinical-stage assets, which can consume cash quickly.
What is the LGND stock price today?
The last price recorded for Ligand Pharmaceuticals Incorporated (LGND), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LGND price target?
The analyst consensus price target for Ligand Pharmaceuticals Incorporated (LGND), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 44 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold LGND
Funds in our ETF coverage that list LGND among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Validea Market Legends ETF (VALX) | 1.87% |